Cargando…

MET amplification as a potential therapeutic target in gastric cancer

Our aim was to investigate both the prevalence of MET amplification in gastric cancer as well as the potential of this genetic alteration to serve as a therapeutic target in gastric cancer. MET amplification was assessed by initial screening with a PCR-based copy number assay followed by confirmator...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawakami, Hisato, Okamoto, Isamu, Arao, Tokuzo, Okamoto, Wataru, Matsumoto, Kazuko, Taniguchi, Hirokazu, Kuwata, Kiyoko, Yamaguchi, Haruka, Nishio, Kazuto, Nakagawa, Kazuhiko, Yamada, Yasuhide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2012
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702203/ https://www.ncbi.nlm.nih.gov/pubmed/23327903

Ejemplares similares

Targeting MET Amplification as a New Oncogenic Driver
por: Kawakami, Hisato, et al.
Publicado: (2014)

SRPX2 Is a Novel Chondroitin Sulfate Proteoglycan That Is Overexpressed in Gastrointestinal Cancer
por: Tanaka, Kaoru, et al.
Publicado: (2012)

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
por: Kawakami, Hisato, et al.
Publicado: (2014)

Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma
por: Kawakami, Hisato, et al.
Publicado: (2013)

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma
por: KATO, HIROAKI, et al.
Publicado: (2013)

Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter
por: SAKAI, KAZUKO, et al.
Publicado: (2015)

Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma
por: Hayashi, Hidetoshi, et al.
Publicado: (2014)

Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production
por: Togashi, Yosuke, et al.
Publicado: (2013)

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
por: Takegawa, Naoki, et al.
Publicado: (2015)

Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples
por: Ishii, Hidenobu, et al.
Publicado: (2015)

Overexpression of heparan sulfate 6-O-sulfotransferase-2 in colorectal cancer
por: HATABE, SHIGERU, et al.
Publicado: (2013)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
por: Takakura, Toshiaki, et al.
Publicado: (2023)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI
por: Yonesaka, Kimio, et al.
Publicado: (2019)

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
por: Sakai, Hitomi, et al.
Publicado: (2018)

Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells
por: Okamoto, W, et al.
Publicado: (2011)

Development of On-Chip Multi-Imaging Flow Cytometry for Identification of Imaging Biomarkers of Clustered Circulating Tumor Cells
por: Kim, Hyonchol, et al.
Publicado: (2014)

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts
por: Kato, Ryoji, et al.
Publicado: (2020)

FGFR2 gene amplification and clinicopathological features in gastric cancer
por: Matsumoto, K, et al.
Publicado: (2012)

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
por: Takeda, Masayuki, et al.
Publicado: (2019)

A Case of Pulmonary Tumor Thrombotic Microangiopathy Suggested by the Presence of Tumor Cells in Peripheral Blood
por: Kawanaka, Yusuke, et al.
Publicado: (2020)

Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells
por: Tamura, Daisuke, et al.
Publicado: (2013)

Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib
por: Takeda, Masayuki, et al.
Publicado: (2014)

Clinical development of nintedanib for advanced non-small-cell lung cancer
por: Takeda, Masayuki, et al.
Publicado: (2015)

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer
por: Watanabe, Satomi, et al.
Publicado: (2018)

Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy‐induced colitis
por: Sakurai, Toshiharu, et al.
Publicado: (2021)

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer
por: Takezawa, K, et al.
Publicado: (2011)

A Microarray-Based Gene Expression Analysis to Identify Diagnostic Biomarkers for Unknown Primary Cancer
por: Kurahashi, Issei, et al.
Publicado: (2013)

Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)
por: Sakai, Kazuko, et al.
Publicado: (2020)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine
por: Hatanaka, Yutaka, et al.
Publicado: (2021)

New Era for Next-Generation Sequencing in Japan
por: Takeda, Masayuki, et al.
Publicado: (2019)

Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection
por: Shoji, Hirokazu, et al.
Publicado: (2014)

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib
por: Hibi, Masaaki, et al.
Publicado: (2016)

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
por: Yonesaka, Kimio, et al.
Publicado: (2019)

PLEKHA5 regulates the survival and peritoneal dissemination of diffuse-type gastric carcinoma cells with Met gene amplification
por: Nagamura, Yuko, et al.
Publicado: (2021)

Impact of MET inhibition on small‐cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway
por: Taniguchi, Hirokazu, et al.
Publicado: (2017)

Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy
por: Tanaka, Yosuke, et al.
Publicado: (2015)

Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies
por: Takahashi, Naoki, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v82daks8q7ff5kde0c048mkhkd